Mycophenolate mofetil monotherapy in liver transplantation: 5-year follow-up of a prospective randomized trial

Transplantation

Volumn 92, Issue 8, 2011, Pages 923-929

  Schmeding, Maximilian ^a,b   Kiessling, Anja ^b   Neuhaus, Ruth ^b   Heidenhain, Christoph ^a,b   Bahra, Marcus ^b   Neuhaus, Peter ^b   Neumann, Ulf P ^a,b  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Immunosuppression; Liver transplantation; MMF; Mycophenolate mofetil; Rejection

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN A; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; AUTOIMMUNE HEPATITIS; BASAL CELL CARCINOMA; BREAST CANCER; CHRONIC GRAFT REJECTION; COLORECTAL CARCINOMA; CONTROLLED STUDY; DIABETES MELLITUS; DIARRHEA; DRUG TREATMENT FAILURE; FEMALE; FIBROSIS; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN TISSUE; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY DISEASE; KIDNEY FUNCTION; LARYNX CARCINOMA; LEUKEMIA; LIVER BIOPSY; LIVER TRANSPLANTATION; LIVER TUMOR; LUNG CANCER; LUNG EMBOLISM; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PANCREAS CANCER; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; STOMACH CANCER; STROKE; SURVIVAL;

ADULT; FEMALE; FIBROSIS; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PROSPECTIVE STUDIES; TREATMENT FAILURE;

EID: 81155159840     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31822d880d     Document Type: Article

References (23)

1. Wiesner RH, Shorr JS, Steffen BJ, et al. Mycophenolate mofetil combination therapy improves long-term outcomes after liver transplantation in patients with and without hepatitis C. Liver Transpl 2005; 11: 750.
2. Koch RO, Graziadei IW, Schulz F, et al. Long-term efficacy and safety of mycophenolate mofetil in liver transplant recipients with calcineurin inhibitor-induced renal dysfunction. Transpl Int 2004; 17: 518.
3. Karie-Guigues S, Janus N, Saliba F, et al. Long-term renal function in liver transplant recipients and impact of immunosuppressive regimens (calcineurin inhibitors alone or in combination with mycophenolate mofetil): The TRY study. Liver Transpl 2009; 15: 1083.
4. Orlando G, Baiocchi L, Cardillo A, et al. Switch to 1.5 grams MMF monotherapy for CNI-related toxicity in liver transplantation is safe and improves renal function, dyslipidemia, and hypertension. Liver Transpl 2007; 13: 46.
5. Bilbao I, Castells L, Rojas L, et al. Immunosuppression based on mycophenolate mofetil in stable liver transplanted patients. Int Immunopharmacol 2006; 6: 1977.
6. Pfitzmann R, Klupp J, Langrehr JM, et al. Mycophenolatemofetil for immunosuppression after liver transplantation: A follow-up study of 191 patients. Transplantation 2003; 76: 130.
7. Tredger JM, Brown NW, Adams J, et al. Monitoring mycophenolate in liver transplant recipients: Toward a therapeutic range. Liver Transpl 2004; 10: 492.
8. Moreno JM, Rubio E, Gómez A, et al. Effectiveness and safety of mycophenolate mofetil as monotherapy in liver transplantation. Transplant Proc 2003; 35: 1874.
9. Moreno Planas JM, Cuervas-Mons Martinez V, Rubio Gonzalez E, et al. Mycophenolate mofetil can be used as monotherapy late after liver transplantation. Am J Transplant 2004; 4: 1650.
10. Schlitt HJ, Barkmann A, Böker KH, et al. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: A randomised controlled study. Lancet 2001; 357: 587.
11. Stewart SF, Hudson M, Talbot D, et al. Mycophenolate mofetil monotherapy in liver transplantation. Lancet 2001; 357: 609.
12. Kamphues C, Bova R, Röcken C, et al. Safety of mycophenolate mofetil monotherapy in patients after liver transplantation. Ann Transplant 2009; 14: 40.
13. Ko HH, Greanya E, Lee TK, et al. Mycophenolate mofetil in liver transplant patients with calcineurin-inhibitor-induced renal impairment. Ann Hepatol 2008; 7: 376.
14. Lake JR, David KM, Steffen BJ, et al. Addition of MMF to dual immunosuppression does not increase the risk of malignant short-term death after liver transplantation. Am J Transplant 2005; 5: 2961.
15. Evans HM, McKiernan PJ, Kelly DA. Mycophenolate mofetil for renal dysfunction after pediatric liver transplantation. Transplantation 2005; 79: 1575.
16. Pierini A, Mirabella S, Brunati A, et al. Mycophenolate mofetil monotherapy in liver transplantation. Transplant Proc 2005; 37: 2614.
17. Fairbanks KD, Thuluvath PJ. Mycophenolate mofetil monotherapy in liver transplant recipients: A single center experience. Liver Transpl 2004; 10: 1189.
18. Reich DJ, Clavien PA, Hodge EE. Mycophenolate mofetil for renal dysfunction in liver transplant recipients on cyclosporine or tacrolimus: Randomized, prospective, multicenter pilot study results. Transplantation 2005; 80: 18.
19. Sampaio EL, Pinheiro-Machado PG, Garcia R, et al. Mycophenolate mofetil vs. sirolimus in kidney transplant recipients receiving tacrolimusbased immunosuppressive regimen. Clin Transplant 2008; 22: 141.
20. Schnitzbauer AA, Zuelke C, Graeb C, et al. A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTORinhibitor- free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. BMC Cancer 2010; 10: 190.
21. Budde K, Becker T, Arns W, et al. Everolimus-based, calcineurininhibitor- free regimen in recipients of de-novo kidney transplants: An open-label, randomised, controlled trial. Lancet 2011; 377: 837.
22. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461.
23. Ormonde DG, de Boer WB, Kierath A, et al. Banff schema for grading liver allograft rejection: Utility in clinical practice. Liver Transpl Surg 1999; 5: 261.